lenvatinib

• 

Lenvatinib plus pembrolizumab shows promise in solid tumours

By Sharon Kell|2020-01-31T17:27:07+00:0031 Jan 2020|Drug treatments|

The combination of lenvatinib plus pembrolizumab has shown promise in [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab shows promise in solid tumours

• 

SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

By Sharon Kell|2019-11-12T09:10:10+00:0012 Nov 2019|Drug treatments|

We are delighted to announce that the Scottish Medicines Consortium (SMC), [...]

Read More

Comments Off on SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

• 

Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer

By Sharon Kell|2019-11-06T17:46:10+00:006 Nov 2019|Drug treatments|

Interim results from an ongoing clinical trial of lenvatinib and [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer

• 

Current role of mTOR inhibitors in metastatic kidney cancer

By Sharon Kell|2019-01-04T09:01:44+00:004 Jan 2019|Drug treatments|

The following video interview with Dr Eric Jonasch, from the [...]

Read More

Comments Off on Current role of mTOR inhibitors in metastatic kidney cancer

• 

Lenvatinib plus pembrolizumab shows promise for metastatic kidney cancer

By Sharon Kell|2018-06-07T13:41:25+00:007 Jun 2018|Drug treatments|

The results from the renal cell carcinoma (RCC) group of [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab shows promise for metastatic kidney cancer

Tyrosine kinase inhibitors for kidney cancer: Past, present and future

By Sharon Kell|2018-02-19T10:13:31+00:0019 Feb 2018|Drug treatments|

In his keynote lecture at the American Society for Clinical Oncology Genitourinary [...]

Read More

Comments Off on Tyrosine kinase inhibitors for kidney cancer: Past, present and future

Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA

By Sharon Kell|2018-01-10T14:51:13+00:0010 Jan 2018|Drug treatments|

The US Food and Drug Administration (FDA) have granted Breakthrough [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA

Sequencing of treatments for advanced kidney cancer remains uncertain

By Sharon Kell|2018-01-09T14:28:59+00:009 Jan 2018|Drug treatments|

There are now a number of licensed drug options available [...]

Read More

Comments Off on Sequencing of treatments for advanced kidney cancer remains uncertain

Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

By Sharon Kell|2017-12-08T09:36:50+00:008 Dec 2017|Drug treatments|

Fantastic news for people with advanced kidney cancer: the lenvatinib [...]

Read More

Comments Off on Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

The evolving management of advanced renal cell carcinoma

By Sharon Kell|2017-12-07T14:20:44+00:007 Dec 2017|Drug treatments|

This article, published in UroToday this week, is a nice summary [...]

Read More

Comments Off on The evolving management of advanced renal cell carcinoma